Nicotine produces behavioral effects through a diverse family of nicotinic acetylcholine receptors (nAChRs). Nicotine-evoked dopamine release is thought to play an important role in the establishment and maintenance of nicotine dependence, which undelies peoples' continued use of tobacoo products, despite their well-known dangers to health. alpha-conotoxin MII is a toxin isolated from the predatory cone-snail Conus magus, which distinguishes between subsets of nicotinic receptors. In the first funding periods of this grant, we used alpha-CtxMII to identify and analyse the nAChR populations that modulate nicotine-evoke dopamine release. We also began to study the effects of chronic nicotine exposure on these receptors, and how they are affected in models of Parkinson's Disease. In order to enhance the usefulness of alpha-CtxMII, we have also engineered variants which have incorporate new properties or increased its selectivity for particular nAChR populations. Experiments outlined in the current proposal will extend these studies further. 1) Chronic treatment and nicotinic subunit mutation will be used (alone, and in combination) to investigate how the nAChR populations characterized in the previous funding period interact with each other, and with the neurotransmitter systems that they modulate. 2) New alpha-CtxMII derivatives will be developed with two aims. First, to make alpha3beta2-nAChR subtype selective derivatives (we do not have such a compound at present, but this is a natually-expressed nAChR subtype that requires further study). Second, to produce alpha-CtxMII-based radiolabels that retain the original selectivity of [125l]alpha-CtxMII (which was developed in the previous funding periods), but with improved assay performance. This will improve out ability to measure and study these important nAChRs. 3) Synthesize and characterize derivatives of alpha-conotoxin ArIB, which has selectivity for alpha7-subtype nAChRs. We intend to develop a series of useful, highly-selective tools for the study of this naturally-occurring nAChR subtype. The proposed studies will provide further insights into the locations, numbers and functional roles of naturally-occurring nAChRs, and the interactions between them. It is likely that this increased understanding will, in turn, illuminate which nAChR subtypes are implicated in nicotine dependence, and thus assist in attempts to develop more-effective smoking cessation aids. These insights may also guide the design of nicotinic therapies for other conditions. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
7R01DA012242-10
Application #
7502060
Study Section
Special Emphasis Panel (ZRG1-MDCN-C (02))
Program Officer
Hillery, Paul
Project Start
1999-02-01
Project End
2012-08-31
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
10
Fiscal Year
2008
Total Cost
$307,704
Indirect Cost
Name
St. Joseph's Hospital and Medical Center
Department
Type
DUNS #
131606022
City
Phoenix
State
AZ
Country
United States
Zip Code
85013
Lucero, Linda M; Weltzin, Maegan M; Eaton, J Brek et al. (2016) Differential ?4(+)/(-)?2 Agonist-binding Site Contributions to ?4?2 Nicotinic Acetylcholine Receptor Function within and between Isoforms. J Biol Chem 291:2444-59
Hone, Arik J; McIntosh, J Michael; Azam, Layla et al. (2015) ?-Conotoxins Identify the ?3?4* Subtype as the Predominant Nicotinic Acetylcholine Receptor Expressed in Human Adrenal Chromaffin Cells. Mol Pharmacol 88:881-93
Marks, Michael J; O'Neill, Heidi C; Wynalda-Camozzi, Kelly M et al. (2015) Chronic treatment with varenicline changes expression of four nAChR binding sites in mice. Neuropharmacology 99:142-55
Eaton, J Brek; Lucero, Linda M; Stratton, Harrison et al. (2014) The unique ?4+/-?4 agonist binding site in (?4)3(?2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (?4)2(?2)3 subtype. J Pharmacol Exp Ther 348:46-58
Marks, Michael J; Grady, Sharon R; Salminen, Outi et al. (2014) ?6?2*-subtype nicotinic acetylcholine receptors are more sensitive than ?4?2*-subtype receptors to regulation by chronic nicotine administration. J Neurochem 130:185-98
Luo, Sulan; Zhangsun, Dongting; Schroeder, Christina I et al. (2014) A novel ?4/7-conotoxin LvIA from Conus lividus that selectively blocks ?3?2 vs. ?6/?3?2?3 nicotinic acetylcholine receptors. FASEB J 28:1842-53
Wang, Yuexiang; Lee, Jang-Won; Oh, Gyeon et al. (2014) Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function ?6* nAChRs. J Neurochem 129:315-27
Soll, Lindsey G; Grady, Sharon R; Salminen, Outi et al. (2013) A role for *4(non-*6)* nicotinic acetylcholine receptors in motor behavior. Neuropharmacology 73:19-30
Marks, Michael J (2013) Genetic matters: thirty years of progress using mouse models in nicotinic research. Biochem Pharmacol 86:1105-13
O'Neill, Heidi C; Laverty, Duncan C; Patzlaff, Natalie E et al. (2013) Mice expressing the ADNFLE valine 287 leucine mutation of the ?2 nicotinic acetylcholine receptor subunit display increased sensitivity to acute nicotine administration and altered presynaptic nicotinic receptor function. Pharmacol Biochem Behav 103:603-21

Showing the most recent 10 out of 78 publications